Fiscal Year 2025 Financial Guidance
For fiscal year 2025:
- The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
- The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.
- The Company continues to expect Med Device net sales to be flat.
- The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.
- The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024.
| Guidance Metric | Guidance Action | Current Guidance (As of Apr. 2, 2025) | Previous Guidance (Issued on Jan. 8, 2025) |
| Net Sales | Increased | $285 - $288 million | $282 - $288 million |
| Med Tech Net Sales Growth | Increased | 14 - 16% | 12 - 15% |
| Med Device Net Sales Growth | Unchanged | Flat (unchanged) | Flat |
| Gross Margin | Increased | 53 - 54% | 52 - 53% |
| Adjusted EBITDA | Increased | $4.0 - $5.0 million | $1.0 - $3.0 million |
| Adjusted EPS | Increased | ($0.31) - ($0.34) | ($0.34) - ($0.38) |
